June 23, 2017 7:04 AM ET

Biotechnology

Company Overview of Karus Therapeutics Limited

Company Overview

Karus Therapeutics Limited designs and develops cancer therapies. The company’s portfolio includes orally-active small molecule drugs, such as KA2237, a dual-selective inhibitor of PI3K isoforms, such as p110ß and p110d for treating hematological and solid tumors; and KA2507 (HDAC6) for PD-L1 expressing tumors. The company was incorporated in 2005 and is based in Oxfordshire, United Kingdom.

Genesis Building

Library Avenue

Harwell Campus

Oxfordshire,  OX11 0SG

United Kingdom

Founded in 2005

Phone:

44 1235 829140

Fax:

44 1235 420517

Key Executives for Karus Therapeutics Limited

Chief Financial Officer
Age: 50
Chief Operating Officer, Chief Scientific Officer and Director
Chief Medical Officer
Head of Preclinical Development
Compensation as of Fiscal Year 2016.

Karus Therapeutics Limited Key Developments

Karus Therapeutics Limited Presents at 9th Annual Conference Biotech Showcase, Jan-09-2017

Karus Therapeutics Limited Presents at 9th Annual Conference Biotech Showcase, Jan-09-2017 . Venue: HILTON SAN FRANCISCO UNION SQUARE, 333 O'Farrell Street, San Francisco, CA 94102, United States.

Karus Therapeutics Limited Presents at BIO Europe 2016 Conference, Nov-08-2016 10:30 AM

Karus Therapeutics Limited Presents at BIO Europe 2016 Conference, Nov-08-2016 10:30 AM. Venue: KoelnMesse - Congress Center North, Cologne, Germany.

Karus Therapeutics Announces First Lymphoma Patients Dosed with KA2237 in Clinical Study

Karus Therapeutics announced that the first patients have been dosed in a Phase I study for its lead candidate, KA2237. This is the Company’s first product to enter clinical trials. KA2237 is a dual-selective inhibitor of two PI3K isoforms, p110ß and p110d. Inhibiting these two isoforms combines an immunotherapeutic response and a direct effect on tumor growth, through selective, targeting of the PI3K pathway. Karus believes that KA2237 has broad therapeutic applicability in the treatment of hematological and solid tumors, as a single agent and in combination with other drugs. This study forms part of the pre-clinical and clinical collaboration between Karus and the University of Texas MD Anderson Cancer Center. The first part of the trial has been designed to assess the safety of KA2237 alone in relapsed, treatment-resistant B cell lymphoma patients. An expansion cohort study will follow and is scheduled to start in 2017. Karus anticipates that up to 40 patients will be treated over the entire study. The agreement with MD Anderson covers a number of preclinical studies of Karus’s two cancer programs, KA2237 and KA2507, with a focus on identifying optimal drug combinations and the appropriate patient populations for further clinical development. The second program, KA2507, a selective-HDAC6 inhibitor, also has both a targeted therapy and immunotherapeutic action and has potential in the treatment of multiple myeloma, B- and T-cell lymphomas and PD-L1 expressing hematological and solid tumors.

Similar Private Companies By Industry

Company Name Region
Abcellute Ltd. Europe
Abcodia Ltd. Europe
Abeterno Ltd. Europe
Abgentis Limited Europe
Achilles Therapeutics Ltd. Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Karus Therapeutics Limited, please visit www.karustherapeutics.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.